Venture Capital

USA Rare Earth is accelerating its timeline to mine critical minerals by two years. Can innovative tech and bold strategy break foreign supply chain dominance?

Daré Bioscience is targeting a 20M-woman market with a novel arousal cream. This is the story of its clever regulatory strategy and high-stakes bet.

Beyond webinars, ON24's G2 win and LinkedIn pact reveal a strategic shift to AI-driven data and connected campaigns in the B2B marketing tech war.

With a key FAA filing, Electra's hybrid-electric EL9 moves closer to reality, promising to bypass airports with 150-foot takeoffs and landings.

The space firm secures vital cash through a complex warrant deal, but at what cost to shareholders? All eyes are now on a critical investor vote.

Behind EVs, AI, and medical breakthroughs lies a hidden process. Discover how ion implantation shapes the chips that power our future and our trust in it.

A new partnership signals a shift towards versatile, American-made drone systems, streamlining critical missions and challenging market incumbents.

The ESA's new elite summit, iicon, replaces E3, targeting C-suites to leverage gaming tech across healthcare, finance, and media. What's at stake?

New data shows Kazia's paxalisib dismantles metastatic drivers and reignites immunity, signaling a strategic disruption in advanced breast cancer treatment.

As drone attacks paralyze European airports, an Israeli tech firm's 'soft kill' net system emerges as a key contender for NATO's defense strategy.

With $47.5M and a veteran CEO, PsiThera is using its advanced AI platform to develop oral medicines for diseases long-dominated by injectable biologics.

Professor Youmin Xi's recent honor signals more than academic success. It marks a strategic blueprint for cultivating the next generation of life science leaders.

A global service provider has cracked the code on talent retention. What can the defense and aerospace sectors learn from its people-first strategy?

A Texas battery plant is online in record time thanks to a Chinese robotics firm. Discover the 'factory in a box' strategy transforming industrial deployment.

Behind the rise of regional streaming giant Chaupal lies a massive tech overhaul. Discover how a B2B partnership enabled a seamless 10M user migration.

A novel drug for heart failure shows promising safety and efficacy data, potentially disrupting a multi-billion dollar market and validating a key investor's strategy.

Bill Ackman's fund is buying back its own shares at a deep discount. We explore the innovative financial strategy and its impact on shareholder value.

Hexagon Purus erases a $12.9M debt in its Panasonic battery deal but gives up lucrative US tax credits, a move securing its supply chain at a high cost.

A Chinese biotech is pioneering next-gen cancer drugs that promise higher precision and fewer side effects. Is this the future of oncology treatment?

The junior explorer is terminating its NWA project option to double down on promising uranium anomalies in Wyoming and a major conductive corridor in Athabasca.